SUMM.L Regulatory News (SUMM)

8 Jun 2006 11:13

VASTox plc08 June 2006 VASTox plc ("VASTox" or "the Company") RESULT of AGM VASTox (AIM: VOX), a leading chemical genomics company, is pleased to announcethat all of the resolutions at the AGM of the Company, held today, were dulypassed. 8 June 2006 For more information please contact: VASTox Tel: +44 (0)1235 443910 Steven Lee, PhD, Chief Executive OfficerDarren Millington, Chief Financial Officer Citigate Dewe Rogerson Tel: +44 (0)207 638 9571 David Dible / Mark Swallow / Valerie Auffray About VASTox VASTox is a chemical genomics technology company that discovers and developsproprietary novel drugs and provides services to the pharmaceutical industry.The company's most advanced drug development programme is focused on developinga new treatment for Duchenne muscular dystrophy based on the up-regulation ofutrophin. A second drug development programme for spinal muscular atrophy isalso progressing rapidly. VASTox has three additional programmes focused onosteoarthritis, cancer and tuberculosis that are expected to be out-licensedprior to entering the clinic. The company's technology platform, which uses zebrafish and fruitflies, has thepotential to dramatically decrease the time and cost of drug discovery anddevelopment. This is because using whole organisms allows it to carry out highvolume, high content screening that delivers data which is highly predictive ofthe efficacy and toxicity of potential drug compounds in humans. VASTox isgrowing revenues based on marketing its unique technology platform and itschemistry expertise. The company listed on the AIM market of the London StockExchange in October 2004. This information is provided by RNS The company news service from the London Stock Exchange